FDA’s AI rollout gets cautiously optimistic reception

Stakeholders are striking a measured tone on the Food and Drug Administration’s announcement that it will swiftly roll out the use of artificial intelligence-assisted reviews across the whole agency, saying there are reasons for concern but it’s necessary to take innovative steps to speed up medical product reviews, Inside Health Policy reported.

Brigham Hyde, cofounder and CEO of the health data company Atropos Health, told Inside Health Policy June 3 that FDA’s AI tool will likely work well for...